Celldex Therapeutics To Test CDX-0159 In Chronic Itchy Skin Disorder

By Vandana Singh14 days ago

  • Celldex Therapeutics Inc (NASDAQ: CLDX) will expand the clinical development of CDX-0159 into prurigo nodularis (PN), a chronic skin disease characterized by the development of hard, intensely itchy (pruritic) nodules on the skin.
  • In a Phase 1a single-dose, healthy volunteer study, CDX-0159 demonstrated durable plasma tryptase reductions indicative of systemic mast cell suppression/ablation.
  • The company is evaluating CDX-0159 ...

Full story available on Benzinga.com

Continue read on benzinga.com